Gout Market Research Report – Forecast to 2027

Gout Market Research Report: By Type (Tophaceous Gout and Pseudogout), By Treatment (Medication, Self-Care), By Diagnosis (Ct Scan, Ultrasound, Urine Test, Blood Test), And By End-User (Hospitals, Specialty Centers, Homecare) – Global Forecast Till 2027

ID: MRFR/Pharma/4453-HCR | | Region: Global | 100 pages         

Gout Market

Gout Market is expected to register a CAGR of 9.23% to reach USD 10.3 billion by 2030.


By Type Tophaceous Gout Pseudogout
By Treatment Medication Self-Care
By Diagnosis Ct Scan Ultrasound Urine Test Blood Test
By End-User Hospitals Specialty Centers Homecare

Key Players

  • Takeda Pharmaceutical Company Ltd.
  • Savient Pharmaceuticals
  • AstraZeneca plc
  • Merck& Co.
  • Inc.Ardelyx
  • Astellas Pharma Inc.
  • Novartis AG


  • Increasing prevalence of obesity
  • rise in cigarette smoking population
Speak to Analyst Request a Free Sample

Gout Market Scenario

Gout is a common form of inflammatory arthritis. Gout is caused due to higher levels of uric acid in the blood. Major risk factors that are likely to cause gout are certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid. Additionally, factors such as diet containing red meat, obesity, and high consumption of alcohol can cause gout.

The gout market is majorly driven by the increasing prevalence of obesity, rising older population leading to rise in the patient population, the rise in cigarette smoking population, and growing mass young population inclined towards a sedentary lifestyle. Additionally, factors such as government initiatives and support, rising demand for advanced treatment, and growing market players offering newer products are likely to drive the market.

According to the United Nations, in 2017 approximately over 962 million population was aged over 60 and above globally. The United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This increasing aging population is likely to propel the growth of the gout market. Factors that are likely to hamper the growth of the market are the lack of awareness about the symptoms of the disease.

Gout market is expected to grow at a CAGR of 8.4% during the forecast period.

Figure:  Gout Market, by Region, 2016 (%)

 Gout Market, by Region

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis

Intended Audience

  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


The gout market is segmented on the basis of treatment, type, end-user, and diagnosis. 

On the basis of type, the market is segmented into tophaceous gout and pseudogout.

On the basis of treatment, the market is segmented into medications and self-care. The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.

On the basis of diagnosis, the market is segmented into X-ray, CT scan, blood test, MRI, ultrasound, urine test, and others.

On the basis of end-user, the market is segmented into hospitals, specialty centers, and homecare.

Research Methodology

 Gout Market,Methodology

Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview, Annual Report, White Paper, Company Presentation, and Market Research Future Analysis

Regional Analysis

The North American gout market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing number of passive smokers, along with the increasing older population is likely to drive the market. Additionally, the growing healthcare expenditure and increasing demand for technologically advanced treatments and products along with the increasing government support are likely to enhance the growth of the gout market in North America. Additionally, according to a survey conducted by the National Centre for Health Statistics, in the year 2014, around 70% of adults were considered to be obese in the U.S.

Europe is the second largest market and holds a healthy share in the gout market. The European market is expected to register a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and increasing skilled medical professionals along with growing need for better healthcare infrastructure. Furthermore, increasing older population, along with the growing inclination towards sedentary lifestyle are driving the growth of the gout market. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to drive the growth of the gout market.

Asia Pacific is expected to be the fastest growing market due to increasing prevalence of chronic gout. China is the fastest growing region owing to an increasingly older population. The increasing awareness about the health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and improvement in the standard of living are driving the growth of the gout market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and increasing availability of specialty care centers.

Key Players                                                                                                         

Some of the key players in the gout market are Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co. Inc., Inc.Ardelyx, Inc., Astellas Pharma Inc., and Novartis AG.

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Gout Market CAGR would be 8.4% during the forecast period.

Diagnosis segments in Gout Market report are CT scan, X-ray, MRI, ultrasound, blood test, urine test, and others.

End users mentioned in Gout Market report are specialty centers, hospitals, and homecare.

North America would lead Gout Market growth.

The Asia Pacific market would register the fastest Gout Market growth.